Citations

Clear

14 citation(s) found for "Deng, Wei".

Targeting the S100A2–RAGE Pathway Restores AT2 Cell Identity and Mitigates Lung Fibrosis
Zhou, Changli , Bagherpoor, Alireza Jian, Deng, Wei, Tschumperlin, Daniel, Tan, Qi, Wellmerling, Jack H, Wellmerling, Jack , Tschumperlin, Daniel J. , Tan, Qi

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag133 | PMID 42576310 Get It

Abstract Lung fibrosis, including idiopathic pulmonary fibrosis (IPF), represents a spectrum of progressive interstitial lung diseases characterized by disrupted epithelial repair, fibroblast activation, and excess extracellular matrix accumulation. A central feature of fibrotic progression is the loss of alveolar type 2 epithelial (AT2) cell identity and the emergence of aberrant transitional states that fail to support normal regeneration. Based on our re-analysis of multiple publicly available scRNA-seq datasets from the IPF Cell Atlas, S100A2 expression is tightly associated with basal-like reprogramming of AT2 cells and is a top upregulated gene at both mRNA and protein levels in IPF lungs. Furthermore, scRNA-seq data from human lung organoid models reveal that AT2 cells co-cultured with fibroblasts acquire a basal-like phenotype and express high levels of S100A2. Functionally, overexpression of S100A2 in human iPSC-derived lung alveolar epithelial type 2 (iAT2) cells leads to loss of AT2 cellular identity, increased generation of reactive oxygen species, and activation of RAGE signaling pathway. We demonstrate that pharmacologic inhibition of RAGE using Azeliragon preserves AT2 cell populations, associated with reduced oxidative stress in iAT2 cells, and significantly attenuates collagen deposition in bleomycin-induced lung fibrosis models. Collectively, our results indicate that S100A2 is a key driver of epithelial dysfunction in lung fibrosis, promoting loss of AT2 identity, aberrant basal fate acquisition, and persistent epithelial injury. Targeting the unrecognized S100A2–RAGE pathway may offer a new therapeutic strategy to restore epithelial homeostasis in lung fibrosis.
NRG-GY037: A phase III randomized trial of induction chemotherapy and pembrolizumab followed by chemoradiation and pembrolizumab maintenance versus standard chemoradiation and pembrolizumab maintenance in high-risk locally advanced cervical cancer.
Mayadev, Jyoti, Deng, Wei , Kim, Hayeon, Xiao, Ying, Geng, H. , Myers, Tashanna , Garda, Allison Elizabeth, Ayala-Peacock, Diandra Norelle, Ma, Martín, Matulonis, Ursula A., Kuhn, Theresa, Huelsmann, Erica, Mannel, Robert S., Herzog, Thomas J. , Aghajanian, Carol, III, Charles A. Leath, Zamarin, Dmitriy, Lankes, Heather A. , Lea, Jayanthi Sivasothy , Xiao, Ying, Garda, Allison E. , Ayala-Peacock, Diandra N. , Matulonis, Ursula A. , Kuhn, Theresa M , Huelsmann, Erica J., Aghajanian, Carol , Zamarin, Dmitriy

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps5632 Get It

TPS5632 Background: Concurrent chemoradiation therapy (CCRT) is the standard of care for locally advanced cervical cancer (LACC); however, outcomes remain suboptimal in patients with high-risk disease. Recent studies suggest that integration of immunotherapy (IO) with definitive chemoradiation, or induction chemotherapy prior to CCRT improves outcomes. Whether treatment intensification with induction systemic therapy and IO prior to CCRT and IO further improves disease control remains unknown. Induction chemotherapy may reduce tumor burden, eradicate micrometastatic disease, and improve tumor immunogenicity prior to definitive CCRT. Preclinical and clinical data support synergy between systemic therapy or radiotherapy and immune checkpoint blockade, providing the rationale for evaluating an induction strategy incorporating chemotherapy and immunotherapy before standard CCRT with immunotherapy, followed by maintenance immunotherapy. Optional tumor tissue and blood samples will be collected for exploratory correlative analyses, including immune and molecular biomarkers associated with response, resistance, and patterns of failure. Methods: NRG-GY037 is a prospective, multi-institutional phase III randomized trial conducted through NRG Oncology. A total of 336 patients will be enrolled (168 per arm). Patients will be stratified by FIGO stage (III vs. IVA) and presence or absence of para-aortic lymph nodes (N2). The primary endpoint is progression free survival (PFS). The study has 90% power to detect PFS hazard ratio of 0.65 in the experimental arm. Treatment: Patients with previously untreated, high-risk LACC are randomized to receive either induction chemotherapy with pembrolizumab for 6 weeks followed by CCRT with pembrolizumab and pembrolizumab maintenance, or standard CCRT with pembrolizumab followed by pembrolizumab maintenance. Major Eligibility Criteria: Eligible patients have histologically confirmed cervical carcinoma (squamous, adenocarcinoma, or adenosquamous), TNM T3 and T4 disease, N0-2, ECOG performance status 0–1, and no prior definitive therapy for cervical cancer. Current Enrollment Status: The trial is actively accruing patients. No efficacy or safety data are available at the time of submission. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT07061977. Clinical trial information: NCT07061977 .
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Slomovitz, Brian M. , Weroha, S. John , Chon, Hye Sook, Podder, Vivek , Markham, Merry Jennifer , Backes, Floor , Thomas, Eric D. , Tenney, Meaghan , Miller, David S. , Muller, Carolyn Y., Callahan, Michael J. , Liu, J. Rebecca, Teplinsky, Eleonora , Kamat, Aparna A., Chern, Jing‐Yi , Murphy, Martina, Choong, Grace M. , Moore, Elena Diaz, Alvarez, Edwin , Rodgers, William H. , Copeland, Larry J. , Herzog, Thomas J. , Podder, Vivek , Markham, Merry J , Backes, Floor , Tenney, Meaghan Elizabeth , Westin, Shannon N , Miller, David S , Edelson, Mitchell I , Teplinsky, Eleonora , Guy, Michael , Choong, Grace M , O'Malley, David M , Copeland, Larry J , Herzog, Thomas J , Coleman, Robert , Gershenson, David M , Deng, Wei, Chen, Lee-may , Edelson, Mitchell I. , Holman, Laura L. , Lea, Jayanthi Sivasothy , O’Malley, David M. , Coleman, Robert L. , Gershenson, David M.

Mayo Clinic

Journal of Clinical Oncology | December 12, 2025 | Volume: 44 | Issue: 3 | Pages: 153-163

10.1200/jco-25-01348 | PMID 41385758 Get It

PURPOSE Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)–p16–Rb pathway, features shared with hormone receptor–positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Horowitz, Neil S. , Peterson, I., Mannel, Robert S., Thompson, J. S. , Lokich, Elizabeth, Myers, Tashanna , Hanjani, P., O’Malley, David M. , Chung, Ki Y. , Miller, David S. , Dizon, Don S. , Mayadev, Jyoti , Monk, Bradley J. , Peterson, Ivy, Thompson, Spencer , Myers, Tashanna , O'Malley, David M , Miller, David S , Ueland, Frederick R , Dizon, Don S , Miller, Austin , Mayadev, Jyoti S , Leath, Charles A , Monk, Bradley J , Deng, Wei, Miller, Austin

Mayo Clinic

Journal of Clinical Oncology | April 4, 2024 | Volume: 42 | Issue: 16 | Pages: 1914-1921

10.1200/jco.23.02235 | PMID 38574312 Get It

PURPOSE To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS Patients enrolled in a single-arm phase II study. Pretreatment inguinal-femoral nodal assessment was performed. Sixty-four Gy IMRT was prescribed to the vulva, with 50-64 Gy delivered to the groins/low pelvis. Radiation therapy (RT) plans were quality-reviewed pretreatment. C 40 mg/m2 and G 50 mg/m2 were administered once per week throughout IMRT. Complete pathologic response (CPR) was the primary end point. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and adverse events were assessed with Common Terminology Criteria for Adverse Events v 4.0. RESULTS Fifty-seven patients enrolled, of which 52 were evaluable. The median age was 58 years (range, 25-58), and 94% were White. Forty (77%) had stage II or III disease, and all had squamous histology. A median of six chemotherapy cycles (range, 1-8) were received. Eighty-five percent of RT plans were quality-reviewed with 100% compliance to protocol. Seven patients came off trial because of toxicity or patient withdrawal. Of 52 patients available for pathologic assessment, 38 (73% [90% CI, 61 to 83]) achieved CPR. No pelvic exenterations were performed. With a median follow-up of 51 months, the 12-month PFS was 74% (90% CI, 62.2 to 82.7) and the 24-month OS was 70% (90% CI, 57 to 79). The most common grade 3 or 4 adverse events were hematologic toxicity and radiation dermatitis. There was one grade 5 event unlikely related to treatment. CONCLUSION Weekly C and G concurrent with IMRT sufficiently improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.
Technical Note: Integrating an open source Monte Carlo code “MCsquare” for clinical use in intensity‐modulated proton therapy
Younkin, James E. , Souris, Kevin , Huang, Sheng , Augustine, Kurt E., Fatyga, M., Ding, Xiaoning, Cohilis, Marie , Shan, Jie , Stoker, J. , Shen, Jiajian , Augustine, Kurt, Fatyga, Mirek, Bues, Martin , Stoker, Joshua, Shen, Jiajian , Deng, Wei, Lin, Liyong , Liu, Wei

Mayo Clinic

Medical Physics | March 10, 2020 | Volume: 47 | Issue: 6 | Pages: 2558-2574

10.1002/mp.14125 | PMID 32153029 Get It

PurposeTo commission an open source Monte Carlo (MC) dose engine, “MCsquare” for a synchrotron‐based proton machine, integrate it into our in‐house C++‐based I/O user interface and our web‐based software platform, expand its functionalities, and improve calculation efficiency for intensity‐modulated proton therapy (IMPT).MethodsWe commissioned MCsquare using a double Gaussian beam model based on in‐air lateral profiles, integrated depth dose of 97 beam energies, and measurements of various spread‐out Bragg peaks (SOBPs). Then we integrated MCsquare into our C++‐based dose calculation code and web‐based second check platform “DOSeCHECK.” We validated the commissioned MCsquare based on 12 different patient geometries and compared the dose calculation with a well‐benchmarked GPU‐accelerated MC (gMC) dose engine. We further improved the MCsquare efficiency by employing the computed tomography (CT) resampling approach. We also expanded its functionality by adding a linear energy transfer (LET)‐related model‐dependent biological dose calculation.ResultsDifferences between MCsquare calculations and SOBP measurements were <2.5% (<1.5% for ~85% of measurements) in water. The dose distributions calculated using MCsquare agreed well with the results calculated using gMC in patient geometries. The average 3D gamma analysis (2%/2 mm) passing rates comparing MCsquare and gMC calculations in the 12 patient geometries were 98.0 ± 1.0%. The computation time to calculate one IMPT plan in patients’ geometries using an inexpensive CPU workstation (Intel Xeon E5‐2680 2.50 GHz) was 2.3 ± 1.8 min after the variable resolution technique was adopted. All calculations except for one craniospinal patient were finished within 3.5 min.ConclusionsMCsquare was successfully commissioned for a synchrotron‐based proton beam therapy delivery system and integrated into our web‐based second check platform. After adopting CT resampling and implementing LET model‐dependent biological dose calculation capabilities, MCsquare will be sufficiently efficient and powerful to achieve Monte Carlo‐based and LET‐guided robust optimization in IMPT, which will be done in the future studies.
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Secord, Angeles Alvarez , Burdett, Kirsten B. , Owzar, Kouros , Tritchler, David , Sibley, Alexander B. , Starr, Mark D. , Brady, John C. , Lankes, Heather A. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , O’Malley, David M. , Gray, Heidi J. , Boente, Matthew, Burger, Robert A. , Birrer, Michael J. , Bell Burdett, Kirsten , Hurwitz, Herbert I , Fujiwara, Keiichi , O'Malley, David M , Liu, Yingmiao , Bakkum‐Gamez, Jamie N. , Deng, Wei, Nixon, Andrew B.

Mayo Clinic

Clinical Cancer Research | January 9, 2020 | Volume: 26 | Issue: 6 | Pages: 1288-1296

10.1158/1078-0432.ccr-19-0226 | PMID 31919136 Get It

Abstract Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses. Experimental Design: Plasma samples were analyzed via multiplex ELISA technology for seven prespecified biomarkers [IL6, Ang-2, osteopontin (OPN), stromal cell–derived factor-1 (SDF-1), VEGF-D, IL6 receptor (IL6R), and GP130]. The predictive value of each biomarker with respect to PFS and OS was assessed using a protein marker by treatment interaction term within the framework of a Cox proportional hazards model. Prognostic markers were identified using Cox models adjusted for baseline covariates. Results: Baseline samples were available from 751 patients. According to our prespecified analysis plan, IL6 was predictive of a therapeutic advantage with bevacizumab for PFS (P = 0.007) and OS (P = 0.003). IL6 and OPN were found to be negative prognostic markers for both PFS and OS (P &lt; 0.001). Patients with high median IL6 levels (dichotomized at the median) treated with bevacizumab had longer PFS (14.2 vs. 8.7 months) and OS (39.6 vs. 33.1 months) compared with placebo. Conclusions: The inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.
Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations
Ding, Xiaoning, Younkin, James E. , Shen, Jiajian , Patel, Samir H. , Bues, Martin , Schild, Steven E. , Shen, Jiajian , Deng, Wei, Liu, Wei

Mayo Clinic

Medical Physics | November 23, 2019 | Volume: 47 | Issue: 2 | Pages: 745-752

10.1002/mp.13934 | PMID 31758864 Get It

PurposeThe dose‐averaged linear energy transfer (LETd) for intensity‐modulated proton therapy (IMPT) calculated by one‐dimensional (1D) analytical models deviates from more accurate but time‐consuming Monte Carlo (MC) simulations. We developed a fast hybrid three‐dimensional (3D) analytical LETd calculation that is more accurate than 1D analytical model.MethodsWe used the Geant4 MC code to generate 3D LETd distributions of monoenergetic proton beams in water for all energies and used a customized error function to fit the LETd lateral profiles at various depths to the MC simulation. The 3D LETd calculation kernel was a lookup table of these fitted coefficients, and LETd was determined directly from spot energies and voxel coordinates during analytical dose calculations. We validated our new method by comparing the calculated LETd distributions to MC results using 3D Gamma index analysis with 3%/2 mm criteria in 12 patient geometries. The significance of the improvement in Gamma index analysis passing rates over the 1D analytical model was determined using the Wilcoxon rank‐sum test.ResultsThe passing rate of 3D Gamma analysis comparing LETd distributions from the hybrid 3D method and the 1D method to MC simulations was significantly improved from 94.0% ± 2.5% to 98.0% ± 1.0% (P = 0.0003). The typical time to calculate dose and LETd simultaneously using an Intel Xeon E5‐2680 2.50 GHz workstation was approximately 2.5 min.ConclusionsOur new method significantly improved the LETd calculation accuracy compared to the 1D method while maintaining significantly shorter calculation time even comparing with the GPU‐based fast MC code.
Technical Note: Comprehensive evaluation and implementation of two independent methods for beam monitor calibration for proton scanning beam
Shen, Jiajian , Ding, Xiaoning, Hu, Yanle , Kang, Yixiu, Bues, Martin , Shen, Jiajian , Liu, Wei , Deng, Wei

Mayo Clinic

Medical Physics | October 14, 2019 | Volume: 46 | Issue: 12 | Pages: 5867-5875

10.1002/mp.13866 | PMID 31610031 Get It

PurposeTo clinically implement and comprehensively evaluate two independent methods for beam monitor calibration of scanning proton beam.MethodsSeven proton energies that represent the lowest to highest energy proton beams were selected. Single energy layer circular fields of diameter 15 cm with 2.5 mm spot spacing and 10 times of repainting (FS15cm) were designed for all energies. The effective measurement points of Bragg peak chamber (BPC), advanced Markus chamber (AMC) and farmer chamber (FC) were all aligned to 2 cm depth in water using SSD setup. The BPC and AMC were cross‐calibrated with farmer chamber (FC) using the field FS15cm. In order to evaluate BPC's lateral response uniformity, a collimated narrow proton beam (5.8 mm diameter) was delivered to the active area and edge of the BPC. The dose area product (DAP) was measured using two methods by two BPCs, one AMC and one FC. For method 1, a single spot proton beam was delivered to the geometric center of the BPC. For method 2, the fields FS15cm were delivered to FC and AMC, respectively. Accumulated charges by these chambers were converted to DAPs, and the quantitative difference of DAPs between both methods was calculated. The causes of the uncertainties were discussed, and the advantages of the two methods were compared.ResultsThe two BPCs showed different lateral response uniformity. BPC1 has a uniform response from the center up to a radius of 3.5 cm. BPC2 has a uniform response only to 2 cm and the response dropped 1% to 2% at 3.5 cm from center. BPC2 also has significant over‐response compared to BPC1. A 2.2% systematic error would be transferred to DAP if the over‐response from BPC2 was not considered. The DAPs measured by method 1 with two BPCs and by method 2 with FC and AMC were consistent to 0.5%. The major uncertainty component of method 1 is from the cross‐calibration of the BPC.ConclusionsThe two independent methods for DAP were shown to give consistent results, given the sources of uncertainties were carefully addressed in the measurements. Direct measurement of DAP with BPC is very efficient, but it may be subject to more than 2% systematic error if the BPC lateral response is not carefully evaluated.
Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis
Pardanani, Animesh , Wadleigh, Martha , Sirhan, Shireen , Bavisotto, Linda M. , Kowalski, Mark , Niforos, Demi, Tefferi, Ayalew , Gotlib, Jason , Gupta, Vikas , Roberts, Andrew W. , Kawashima, Jun, Lee, Peter , Deng, Wei

Mayo Clinic

Blood | October 12, 2019 | Volume: 122 | Issue: 21 | Pages: 108-108

10.1182/blood.v122.21.108.108 Get It

Abstract Background Momelotinib (MMB, GS-0387, CYT387) is a JAK1 and JAK2 inhibitor under investigation for the treatment of myelofibrosis. Preliminary results of a phase I/II core study (n=166) were previously reported. Subjects who achieved at least stable disease in the core study could continue MMB treatment in an extension study (n=120). Final data from the phase I/II core study and updated data from the extension study are presented. Methods Subjects with myelofibrosis categorized as IPSS intermediate-2 or high risk, or intermediate-1 risk with symptomatic splenomegaly or hepatomegaly and/or unresponsive to available therapy, were enrolled. Following a dose escalation phase, subjects were treated on a dose expansion phase in the core study with MMB at either 150 mg or 300 mg once-daily, or 150 mg twice-daily for 9 months. In the extension study, MMB was at the same dose the subject tolerated and derived clinical benefit from in the core study. Clinical responses were adjudicated according to IWG-MRT criteria. Spleen Response was defined as ≥ 50% reduction in palpable splenomegaly that lasted ≥ 8 weeks (wks) for baseline splenomegaly ≥ 10 cm, plus resolution of palpable splenomegaly that lasted ≥ 8 wks for baseline splenomegaly > 5 to < 10 cm. Anemia Response was defined as transfusion-free interval of ≥ 12 wks for baseline transfusion dependence, plus ≥ 2 g/dL rise in hemoglobin (Hb) for baseline transfusion independence and Hb < 10 g/dL. Baseline transfusion dependence was defined as ≥ 2U RBC transfusion in the 30 days prior to first dose of MMB or identified as transfusion dependent in medical history. Results As of April 2013, 58 of 120 subjects remained on treatment in the open-label extension study, with median treatment duration of 507 days (range 23-1036) for both core and extension studies. Based on interim analysis, the most common reasons for discontinuation from the extension study were disease progression (n=13), investigator's decision (n=12), and consent withdrawal (n=10), with 2 drug-related adverse events (both peripheral neuropathy) that led to study discontinuation. Efficacy data for the core and extension studies are depicted in table below. Median time to onset of Spleen Response was not yet reached (range 6-693 days), median duration of Spleen Response was 324 days (range 56-936). Median duration of 12-week transfusion independence was not yet reached (91-987 days), median duration of Anemia Response was not yet reached (57-987). Constitutional symptoms assessment at 3 months for the core study showed ≥ 50% improvement in 72%, 46%, 77%, 100%, and 74% of subjects with pruritis, cough, bone pain, fever, and night sweats respectively. Most common Grade 3 or 4 treatment-related events were thrombocytopenia (29%), neutropenia (5%), and elevated lipase (4%) without clinical pancreatitis. Peripheral neuropathy was reported by 38% of subjects, all ≤ Grade 2, with 17 subjects experiencing neuropathy at baseline. Four subjects transformed into acute leukemia (1 in core study, 3 in extension study). There was no treatment-related death. Conclusion Prolonged administration of MMB for treatment of myelofibrosis is well tolerated and has an acceptable safety profile. MMB is efficacious in durably reducing myelofibrosis-related splenomegaly as well as improving transfusion requirement and disease-related symptoms. These data form the basis for the phase 3 randomized study of MMB in myelofibrosis. Disclosures: Gupta: Novartis: Lecture fee, Lecture fee Other; Novartis: Consultancy; Incyte: Consultancy; Novartis: Research Funding; Incyte: Research Funding. Bavisotto:YM Biosciences: Consultancy. Kawashima:Gilead Sciences: Employment. Lee:Gilead Sciences: Employment. Kowalski:Gilead Sciences: Employment. Deng:Gilead Sciences: Employment. Niforos:Gilead Sciences: Employment.
Small‐spot intensity‐modulated proton therapy and volumetric‐modulated arc therapies for patients with locally advanced non‐small‐cell lung cancer: A dosimetric comparative study
Liu, Chenbin , Shan, Jie , Daniels, T.B., Rule, William G., Lara, Pedro R., Korte, Shawn M., Shen, Jiajian , Ding, Xiaoning, Daniels, Thomas B, Schild, Steven E. , Bues, Martin , Shen, Jiajian , Sio, Terence T. , Deng, Wei, Shan, Jie, Lara, Pedro R., Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | October 17, 2018 | Volume: 19 | Issue: 6 | Pages: 140-148

10.1002/acm2.12459 | PMID 30328674 Get It

AbstractPurposeTo compare dosimetric performance of volumetric‐modulated arc therapy (VMAT) and small‐spot intensity‐modulated proton therapy for stage III non‐small‐cell lung cancer (NSCLC).Methods and MaterialsA total of 24 NSCLC patients were retrospectively reviewed; 12 patients received intensity‐modulated proton therapy (IMPT) and the remaining 12 received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTV) on averaged 4D‐CTs. The dose‐volume‐histograms (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases of each field per fraction. DVH indices were compared using Wilcoxon rank sum test.ResultsCompared with VMAT, IMPT delivered significantly lower cord Dmax, heart Dmean, and lung V5 Gy[RBE] with comparable CTV dose homogeneity, and protection of other OARs. In terms of plan robustness, the IMPT plans were statistically better than VMAT plans in heart Dmean, but were statistically worse in CTV dose coverage, cord Dmax, lung Dmean, and V5 Gy[RBE]. Other DVH indices were comparable. The IMPT plans still met the standard clinical requirements with interplay effects considered.ConclusionsSmall‐spot IMPT improves cord, heart, and lung sparing compared to VMAT and achieves clinically acceptable plan robustness at least for the patients included in this study with motion amplitude less than 11 mm. Our study supports the usage of IMPT to treat some lung cancer patients.